Table of Contents
Astounding Asthma Inhaler Announcement
Pharmaceutical giant GlaxoSmithKline (GSK) recently announced its decision to discontinue the popular asthma inhaler, Flovent, by 2024. Set to be replaced by an ‘authorized generic’, the move has sparked a wave of concern and uncertainty among the millions of asthma patients who rely on this medication, particularly at the brink of the spring allergy season.
The Generic Replacement Dilemma
The authorized generic, despite being marketed at a slightly lower cash price of around $310 compared to Flovent’s original price of $340, might not necessarily be cheaper for patients. One of the primary reasons for this is the varying nature of insurance coverages. Not all insurance providers cover the cost of the new generic, and even if they do, patients might still end up paying more than they were for the branded version at the pharmacy counter.
Potential Insurance Hurdles
One of the significant challenges faced by patients with the introduction of the authorized generic is the lack of wide insurance coverage for the replacement. This could lead to higher co-pays, a need for new prescriptions, and even the necessity for prior authorizations. It’s worth noting that the American Academy of Pediatrics has reported that some insurers only cover breath-actuated inhalers, which aren’t recommended for children suffering from eosinophilic esophagitis.
Anticipated Impact on Asthma Patients
The discontinuation of Flovent could potentially have a significant impact on asthma patients. According to data from the Centers for Disease Control and Prevention (CDC), in 2021 alone, 9.8 million people experienced an asthma attack, including 1.8 million children and 8 million adults. With such a vast number of people relying on asthma inhalers, the transition to an authorized generic could undoubtedly create disruption.
GSK’s Assurance Amidst Concerns
Despite the rising concerns, GSK has assured that the transition to authorized generics won’t impact their ability to supply the market. They anticipate minimal disruption for patients. However, this switch comes at the height of the respiratory virus season, adding further uncertainty to its potential impact on patients.
Past Controversies and the Ethical Question
This decision by GSK is seen by many as an attempt to avoid accountability for years of significant price increases on Flovent. The price of Flovent has reportedly risen about 47 percent since 2014, and this move raises questions about the ethical considerations of pharmaceutical pricing. The decision has also stirred up past controversies about GSK’s alleged failure to disclose potential side effects and risks associated with the Flovent inhaler, leading to multiple lawsuits.
A Call to Action
With Flovent’s discontinuation looming, it’s crucial for patients to take proactive steps to ensure their health care needs are met. Patients are advised to fill their Flovent prescriptions while they can and start discussions with their doctors and insurance providers about alternative options. As the situation unfolds, it’s clear that this move by GSK serves as a stark reminder about the influence of pharmaceutical companies on the accessibility and affordability of essential medications.
